<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="488">
  <stage>Registered</stage>
  <submitdate>21/10/2004</submitdate>
  <approvaldate>21/10/2004</approvaldate>
  <nctid>NCT00094640</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetic Characterization of Intramuscular Olanzapine Depot</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>F1D-EW-LOBS</secondaryid>
    <secondaryid>6106</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia</healthcondition>
    <healthcondition>Schizoaffective Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Intramuscular Olanzapine Depot

Treatment: drugs: Intramuscular Olanzapine Depot


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Patients must have schizophrenia or schizoaffective disorders.

          -  Each patient must have a level of understanding sufficient to complete all tests and
             examinations required by the protocol, and to provide informed consent.

          -  Patient must not have participated in a clinical trial of another investigational
             drug, including olanzapine, within 1 month (30 days) prior to study entry.

          -  Female patients must not be pregnant or breast-feeding.

          -  Patients must not be experiencing acute, serious, or unstable medical conditions other
             than schizophrenia or schizoaffective disorder.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>76</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. - Adelaide</hospital>
    <postcode> - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Kortenberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Tlalpan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The goals of this study are to:

      Determine the blood levels of intramuscular (IM) olanzapine depot in patients at different
      points in time after an injection, and compare these levels to the amount of olanzapine in
      the blood of patients after treated by oral administration with Zyprexa (olanzapine) tablets
      or by intramuscular administration with Zyprexa IntraMuscular (olanzapine for injection).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00094640</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>